LEE GARY K. (Chief Scientific Officer) sold 0.8% of their position (147.00 shares) of LYELL IMMUNOPHARMA, INC. on the open market
Open‑market sale worth $3.4K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/11/2026ACC: 0001907345-26-000001
Officer· Chief Scientific Officer
Since Jan 2022
+53.85K
Net shares
Net buyer
$3.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
54K acquired · 147.00 disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+4K
Price / share
—
Trade value
—
% of position
27.1%
2/9/2026
14.76K→18.76K
Common Stock
Direct
Shares
−147.00
Price / share
$23.12
Trade value
$3.40K
% of position
0.8%
2/10/2026
18.76K→18.61K
Total
Net shares
+3.85K
Net value
-$3.40K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/9/2026 | A · Award | +4K | — | — | 27.1% | 14.76K | 18.76K |
| Common Stock Direct | 2/10/2026 | S · Sale | −147.00 | $23.12 | $3.40K | 0.8% | 18.76K | 18.61K |
| Total | +3.85K | -$3.40K | ||||||
Derivative Transactions1
Option (right to buy)
Direct
Converts to
Common Stock
50K shares
Shares
+50K
Strike price
23.71
Held after
50K
Exercisable
—
2/10/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Option (right to buy) Direct | Common Stock50K shares | 2/10/2026 | A · Award | +50K | 23.71 | — | 50K |